The company also listed other serious potential side effects, including: Thyroid tumors, including thyroid cancer Pancreatitis (inflammation of the pancreas) Hypoglycemia (low blood sugar) Severe allergic reactions Kidney failure Serious stomach issues Changes in vision These problems have also been associated with Wegovy (semaglutide), produced by Novo Nordisk
Take MASLD and OSA, for example
In clinical trials of Wegovy, discontinuation due to gastrointestinal side effects occurred in approximately 4.5% of participants, while for Zepbound, discontinuation rates due to adverse events (primarily gastrointestinal) ranged from 4.3% to 7.1% depending on dose
Ongoing Care & Adjustments Regular check-ins for progress tracking, measurements, and dose adjustments
Highly recommend for those who qualify